Suppr超能文献

基于适体的核糖开关的治疗应用。

Therapeutic Applications of Aptamer-Based Riboswitches.

作者信息

Lee Chang Ho, Han Seung Ryul, Lee Seong-Wook

机构信息

Department of Molecular Biology, Institute of Nanosensor and Biotechnology, and Research Institute of Advanced Omics, Dankook University , Yongin, Republic of Korea.

出版信息

Nucleic Acid Ther. 2016 Feb;26(1):44-51. doi: 10.1089/nat.2015.0570. Epub 2015 Nov 5.

Abstract

Aptamers bind to their targets with high affinity and specificity through structure-based complementarity, instead of sequence complementarity that is used by most of the oligonucleotide-based therapeutics. This property has been exploited in using aptamers as multifunctional therapeutic units, by attaching them to therapeutic drugs, nanoparticles, or imaging agents, or as direct molecular decoys for inducing loss-of-function or gain-of-function of targets. One of the most interesting fields of aptamer application is their development as molecular sensors to regulate artificial riboswitches. Naturally, the riboswitches sense small-molecule metabolites and respond by regulating the expression of the corresponding metabolic genes. Riboswitches are cis-acting RNA structures that consist of the sensing (aptamer) and the regulating (expression platform) domains. In principle, diverse riboswitches can be engineered and applied to control different steps of gene expression in bacterial species as well as eukaryotes, by simply replacing aptamers against various endogenous and/or exogenous targets. Although these engineered aptamer-based riboswitches are recently gaining attention, it is clear that aptamer-based riboswitches have a potential for next-generation therapeutics against various diseases because of their controllability, specificity, and modularity in regulating gene expression through various cellular processes, including transcription, splicing, stability, RNA interference, and translation. In this review, we provide a summary of the recently developed and engineered aptamer-based riboswitches focusing on their therapeutic availability and further discuss their clinical potential.

摘要

适体通过基于结构的互补性而非大多数基于寡核苷酸的治疗药物所使用的序列互补性,以高亲和力和特异性与靶标结合。通过将适体连接到治疗药物、纳米颗粒或成像剂上,或作为诱导靶标功能丧失或功能获得的直接分子诱饵,这一特性已被用于将适体用作多功能治疗单元。适体应用中最有趣的领域之一是将其开发为调节人工核糖开关的分子传感器。天然的核糖开关可感知小分子代谢物,并通过调节相应代谢基因的表达做出反应。核糖开关是由传感(适体)和调节(表达平台)结构域组成的顺式作用RNA结构。原则上,通过简单地替换针对各种内源性和/或外源性靶标的适体,可设计并应用多种核糖开关来控制细菌和真核生物中基因表达的不同步骤。尽管这些基于工程适体的核糖开关最近受到了关注,但基于适体的核糖开关因其在通过转录(包括转录、剪接、稳定性、RNA干扰和翻译)等各种细胞过程调节基因表达方面的可控性、特异性和模块化,显然具有针对各种疾病的下一代治疗潜力。在本综述中,我们总结了最近开发和工程化的基于适体的核糖开关,重点关注其治疗可用性,并进一步讨论其临床潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验